Splitomicin A Sir2p histone deactylease inhibitor

Splitomicin (CAS 5690-03-9)

Splitomicin | CAS 5690-03-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_358701, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 59ms
  • REVIEWS, PRODUCT
Synonym: 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1-Naphthalen propanoic acid
Application: A Sir2p histone deactylease inhibitor
CAS Number: 5690-03-9
Purity: ≥98%
Molecular Weight: 198.22
Molecular Formula: C13H10O2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Splitomicin is a cell-permeable lactone that acts as a selective inhibitor of Sir2p NAD+-dependent histone deacetylase activity. Splitomicin creates a conditional phenocopy of a sir2 deletion mutant in S. cerevisiae and sensitizes mammalian cells to a variety of DNA-damaging agents by abrogating Sir2p activity on p53. Splitomicin acts by either altering or blocking access to the acetylated histone binding pocket.


References

1. Bedalov, A., et al. 2001. Proc. Natl. Acad. Sci. USA 98: 15113-15118. PMID: 11752457

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO (100 mM), and ethanol (100 mM).
Storage :
Store at 4° C
Melting Point :
50-52° C
Boiling Point :
383.57° C at 760 mmHg (Predicted)
Density :
1.26 g/cm3 (Predicted)
Refractive Index :
n20D 1.66 (Predicted)
IC50 :
NAD+-dependent histone deacetylase activity of Sir2 protein: IC50 = 60 µM; Histone deacetylase: IC50 = >10000 nM (Plasmodium falciparum); NAD-dependent histone deacetylase SIR2: IC50 = 74000 nM (Saccharomyces cerevisiae S288c)
Ki Data :
Nuclear receptor corepressor 2: Ki= >75000 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5269
MDL Number :
MFCD08705254
SMILES :
C1CC(=O)OC2=C1C3=CC=CC=C3C=C2

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 96ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Chapalamadugu Chapalamadugu, KC. et al. (PubMed 25447406) found that Splitomicin caused inhibition of SiRT1 in H9C2 cells. This caused a decrease in SiRT1 and Kv1.5 expression, suggesting that SiRT1 may mediate Kv1.5 downregulation. -SCBT Publication Review
Date published: 2015-07-12
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_358701, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 218ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.